Impact of rheumatoid arthritis (RA) treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial
Authors' conclusion
Both treatment strategies were associated with improved lipid profiles via changes in different lipids and lipoproteins. These effects had no correlation with change in CV risk as measured by vascular inflammation by FDG-PET/CT.
Study context
- Population
- Methotrexate (MTX) inadequate responders with RA; subjects on statin therapy at baseline excludedmedian age 57 years, 76% female
- Participants
- 122 participants
- Comparison
- Triple therapy vs TNFi for 24 weeks in MTX inadequate responders
- Triple therapyn = 61
- TNFin = 61reference
- Primary endpoint
- Change in routine lipids and advanced lipoproteins between baseline and 24 weeks, within and across arms, and their correlation with change in MDS-TBR (FDG-PET/CT arterial inflammation)
- Follow-up
- 24 weeks
Methodological detailsactive comparator
- Active comparator
Primary result
As reported in the abstract
Lipid and lipoprotein change, between arms
- Triple therapy vs TNFi
- larger reduction in triglycerides 15.9 mg/dL; P = 0.01
- Triple therapy vs TNFi
- larger reduction in total cholesterol to HDL-C ratio 0.29; P = 0.01
- Triple therapy vs TNFi
- larger reduction in LDL particle number 111.2; P = 0.02
- TNFi vs Triple therapy
- larger increase in HDL particle number 1.6 umol/L; P = 0.006
Further findings
Correlation between change in lipids and change in MDS-TBR · 24 weeks
- No correlation within and across treatment arms
Original publication
Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Res Ther. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →